Grants & Sponsorships
Ionis Pharmaceuticals funds early-career researchers for innovative projects in Angelman Syndrome and severe hypertriglyceridemia to advance scientific understanding and patient care.
Funder: Ionis Pharmaceuticals
Due Dates: May 29, 2026 (Neurology Ionis Young Investigator Grant) | June 15, 2026 (Cardiometabolic Young Investigator Grant)
Funding Amounts: $50,000/year for up to 2 years per awardee; typically 1–2 awards per program annually.
Summary: Supports early-career investigators in neurology (Angelman Syndrome) and cardiometabolic (severe hypertriglyceridemia) research through competitive, mentored grants.
Key Information: Late or incomplete applications will not be considered.
Description
Ionis Pharmaceuticals offers competitive Young Investigator Grants to support early-career researchers conducting innovative, high-impact projects in neurology (focusing on Angelman Syndrome) and cardiometabolic disorders (focusing on severe hypertriglyceridemia). These grants are designed to foster the next generation of clinical and translational scientists by providing research funding, mentorship, and institutional support for up to two years. The program aims to advance understanding, diagnosis, and patient care in these rare and serious disease areas.
